Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Alemtuzumab Induction With Tacrolimus and MMF Maintenance Immunosuppression in Islet Transplantation

NCT00175253 is registered in ClinicalTrials.gov with University of Alberta as lead sponsor.

NCT NCT00175253
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00175253 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Alemtuzumab Induction With Tacrolimus and MMF Maintenance Immunosuppression in Islet Transplantation
Lead sponsor
University of Alberta
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2005
Completion date
April 30, 2012
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

type 1 diabetes